Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
Focused Update to the Guidelines of Care for Managing Actinic Keratosis
TAKE-HOME MESSAGE
-
This article provides an update on the guidelines of care for the management of actinic keratosis (AK), given the recent US Food and Drug Administration's approval of tirbinabulin. The standard treatment regimen is topical tirbanibulin 1% applied once daily to a 25 cm2 treatment field containing 4 to 8 AKs on the face or scalp for 5 consecutive days.
- A strong recommendation for the use of topical tirbanibulin was added to the list of recommended therapies for AKs, although the cost might be prohibitive.
abstract
This abstract is available on the publisher's site.
Access this abstract now Full Text Available for ClinicalKey SubscribersActinic keratoses are keratinocyte neoplasms occurring on skin that has had long-term exposure to ultraviolet radiation. Actinic keratosis (AK) is one of the most common conditions treated by dermatologists in the United States. In 2021, the AAD published guidelines addressing the management of AK and provided recommendations for the use of various available AK treatments, including topical agents, cryosurgery, and photodynamic therapy. The purpose of the update is to incorporate new evidence for the use of a recently U.S Food and Drug Administration-approved topical, tirbanibulin, for the treatment of AK into the AAD's existing guidance on the management of AK.
Additional Info
Focused update to the Guidelines of Care for the Management of Actinic Keratosis: Executive Summary
J Am Acad Dermatol 2022 Apr 16;[EPub Ahead of Print], DB Eisen, RP Dellavalle, L Frazer-Green, TE Schlesinger, M Shive, PA WuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.